Xtacy Therapeutics Corp. announces expansion of its MDMA research platform to help find solutions to unmet medical needs focused on Perioperative Pain, Social Anxiety Disorder, Hypoactive Sexual Desire Disorder and Anorexia Nervosa. The Company is expanding its' MDMA research platform to pursue financing for clinical trials to include Perioperative Pain, but also Social Anxiety Disorder, Hypoactive Sexual Desire Disorder (HSDD) and Anorexia Nervosa.

There is existing evidence for efficacy in all four indications from studies on MDMA. Leapfrogging some development phases became obvious from the extensive data available from MAPS for both safety and efficacy. This should eliminate the need for additional preclinical, Phase 1 trials - bibliographic data utilization and allow for an accelerated entry into Phase 2 and Phase 3 trials, saving both time and financial resources to the Company.